L1210 leukemia hybrids isolated after fusion of alkylating agent-resistant sublines.
The two resistant lines, L1210/CPA (cyclophosphamide) and L1210/MeCCNU (1-(2-chloroethyl)-3-(trans-4-methyl-cyclohexyl)-1-nitrosourea) were used, each of which is not cross-resistant to the drug to which the other line is resistant. Their resistance was used as markers as well as the basis for selection of the hybrids. For the production of hybrids five in-vivo or in-vitro schedules were employed. The in-vitro methods produced six successful hybrid lines, but the in-vivo schedules produced none. Resistance to both CPA and MeCCNU was expressed dominantly in the hybrids. The hybrids had chromosome modes ranging from 68 to 78. This study shows that CPA and MeCCNU can be used both as markers and as selective agents, and that CPA and MeCCNU resistance in L1210 leukemia are dominantly expressed in the hybrid.
Schmid
F A
FA
Laboratory of Experimental Antitumor Testing, Memorial Sloan-Kettering Cancer Center, New York 10021.
Otter
G M
GM
Hirano
I
I
D000477:Alkylating Agents / Q000494:pharmacology*; D000818:Animals; D002459:Cell Fusion / Q000187:drug effects*; D002460:Cell Line; D002469:Cell Separation / Q000379:methods*; D002875:Chromosomes; D003520:Cyclophosphamide / Q000494:pharmacology; D004351:Drug Resistance; D005260:Female; D006822:Hybrid Cells / Q000473:pathology*; D007939:Leukemia L1210 / Q000235:genetics / Q000473:pathology*; D051379:Mice; D009368:Neoplasm Transplantation; D012673:Semustine / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000477:Alkylating Agents; D012673:Semustine; D003520:Cyclophosphamide